Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 35

1.

Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2.

Rolland M, Edlefsen PT, Larsen BB, Tovanabutra S, Sanders-Buell E, Hertz T, deCamp AC, Carrico C, Menis S, Magaret CA, Ahmed H, Juraska M, Chen L, Konopa P, Nariya S, Stoddard JN, Wong K, Zhao H, Deng W, Maust BS, Bose M, Howell S, Bates A, Lazzaro M, O'Sullivan A, Lei E, Bradfield A, Ibitamuno G, Assawadarachai V, O'Connell RJ, deSouza MS, Nitayaphan S, Rerks-Ngarm S, Robb ML, McLellan JS, Georgiev I, Kwong PD, Carlson JM, Michael NL, Schief WR, Gilbert PB, Mullins JI, Kim JH.

Nature. 2012 Oct 18;490(7420):417-20. doi: 10.1038/nature11519. Epub 2012 Sep 10.

2.

Nonneutralizing functional antibodies: a new "old" paradigm for HIV vaccines.

Excler JL, Ake J, Robb ML, Kim JH, Plotkin SA.

Clin Vaccine Immunol. 2014 Aug;21(8):1023-36. doi: 10.1128/CVI.00230-14. Epub 2014 Jun 11. Review.

3.

The HIV-1 gp120 V1V2 loop: structure, function and importance for vaccine development.

O'Connell RJ, Kim JH, Excler JL.

Expert Rev Vaccines. 2014 Dec;13(12):1489-500. doi: 10.1586/14760584.2014.951335. Epub 2014 Aug 28. Review.

PMID:
25163695
4.

Novel directions in HIV-1 vaccines revealed from clinical trials.

Excler JL, Tomaras GD, Russell ND.

Curr Opin HIV AIDS. 2013 Sep;8(5):421-31. doi: 10.1097/COH.0b013e3283632c26. Review.

5.

Prospects for a globally effective HIV-1 vaccine.

Excler JL, Robb ML, Kim JH.

Vaccine. 2015 Nov 27;33 Suppl 4:D4-12. doi: 10.1016/j.vaccine.2015.03.059. Epub 2015 Jun 20. Review.

PMID:
26100921
6.

Broadly neutralizing antibodies against HIV-1: templates for a vaccine.

van Gils MJ, Sanders RW.

Virology. 2013 Jan 5;435(1):46-56. doi: 10.1016/j.virol.2012.10.004. Review.

7.

Sieve analysis in HIV-1 vaccine efficacy trials.

Edlefsen PT, Gilbert PB, Rolland M.

Curr Opin HIV AIDS. 2013 Sep;8(5):432-6. doi: 10.1097/COH.0b013e328362db2b. Review.

8.

Virological features associated with the development of broadly neutralizing antibodies to HIV-1.

Moore PL, Williamson C, Morris L.

Trends Microbiol. 2015 Apr;23(4):204-11. doi: 10.1016/j.tim.2014.12.007. Epub 2015 Jan 5. Review.

9.

HIV vaccine efficacy and immune correlates of risk.

O'Connell RJ, Excler JL.

Curr HIV Res. 2013 Sep;11(6):450-63. Review.

PMID:
24033301
10.

HIV vaccines: progress to date.

Munier CM, Andersen CR, Kelleher AD.

Drugs. 2011 Mar 5;71(4):387-414. doi: 10.2165/11585400-000000000-00000. Review.

PMID:
21395355
11.

Viral sequence diversity: challenges for AIDS vaccine designs.

McBurney SP, Ross TM.

Expert Rev Vaccines. 2008 Nov;7(9):1405-17. doi: 10.1586/14760584.7.9.1405. Review.

12.

Antibody persistence and T-cell balance: two key factors confronting HIV vaccine development.

Lewis GK, DeVico AL, Gallo RC.

Proc Natl Acad Sci U S A. 2014 Nov 4;111(44):15614-21. doi: 10.1073/pnas.1413550111. Epub 2014 Oct 27. Review.

13.

Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1.

Kwong PD, Mascola JR, Nabel GJ.

Cold Spring Harb Perspect Med. 2011 Sep;1(1):a007278. doi: 10.1101/cshperspect.a007278. Review.

14.

Diversity considerations in HIV-1 vaccine selection.

Gaschen B, Taylor J, Yusim K, Foley B, Gao F, Lang D, Novitsky V, Haynes B, Hahn BH, Bhattacharya T, Korber B.

Science. 2002 Jun 28;296(5577):2354-60. Review.

PMID:
12089434
15.

[Advances in the Immunogenic Design of HIV-1 Vaccine].

Zhang X, Wang T, Yu X.

Bing Du Xue Bao. 2016 Jan;32(1):88-92. Review. Chinese.

PMID:
27295889
16.

Strategies for eliciting HIV-1 inhibitory antibodies.

Tomaras GD, Haynes BF.

Curr Opin HIV AIDS. 2010 Sep;5(5):421-7. doi: 10.1097/COH.0b013e32833d2d45. Review.

17.

Structural insights on the role of antibodies in HIV-1 vaccine and therapy.

West AP Jr, Scharf L, Scheid JF, Klein F, Bjorkman PJ, Nussenzweig MC.

Cell. 2014 Feb 13;156(4):633-48. doi: 10.1016/j.cell.2014.01.052. Review.

18.

A global approach to HIV-1 vaccine development.

Stephenson KE, Barouch DH.

Immunol Rev. 2013 Jul;254(1):295-304. doi: 10.1111/imr.12073. Review.

19.

Preclinical and clinical development of a multi-envelope, DNA-virus-protein (D-V-P) HIV-1 vaccine.

Sealy R, Slobod KS, Flynn P, Branum K, Surman S, Jones B, Freiden P, Lockey T, Howlett N, Hurwitz JL.

Int Rev Immunol. 2009;28(1):49-68. doi: 10.1080/08830180802495605. Review.

20.

No acquisition: a new ambition for HIV vaccine development?

Lakhashe SK, Silvestri G, Ruprecht RM.

Curr Opin Virol. 2011 Oct;1(4):246-53. doi: 10.1016/j.coviro.2011.07.005. Review.

Supplemental Content

Support Center